New ultrasound technique aims to spot cancer more clearly

NCT ID NCT07225114

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new ultrasound imaging method called Contrast Enhanced Super-Resolution (CESR) to see if it can better detect and tell apart cancerous and non-cancerous lesions in the breast, liver, and kidney. It involves 40 participants: 10 healthy volunteers to fine-tune the imaging, and 30 patients with known lesions who will receive an IV contrast agent during the scan. The results will be compared to standard ultrasound and biopsy findings to see if this technique improves diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
perflutren lipid contrast agent
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect and distinguish cancerous lesions in the breast, liver, and kidney.
What could go wrong
This is a small, early-phase study with only 40 participants. The new imaging technique may not prove more accurate than standard ultrasound, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.